Interleukin 2 Activity in Peripheral Blood Mononuclear Cells of Patients with Gynecologic Malignancies

Overview

Journal Med Oncol Tumor Pharmacother

Specialties Oncology
Pharmacology

Date 1988 Jan 1

PMID 3137397

Citations 1

Authors

Y Kikuchi

T Kita

K Oomori

M Miyauchi

I Iwano

I Kizawa

Affiliations

Soon will be listed here.

Abstract

We studied production of, absorption of and response to interleukin 2 (IL-2) by peripheral blood mononuclear cells (PBMC) from 66 patients with gynecologic malignancies, in addition to measurement of the OKT 4/OKT 8 cell ratio. Patients with benign tumor served as controls. The OKT 4/OKT 8 cell ratio in patients with advanced (but not early) gynecologic malignancies was significantly lower than that in patients with benign tumor. PBMC from advanced cancer patients activated with phytohemagglutinin (PHA) had significantly lower IL-2 production compared to that from patients with benign tumors, while significant changes in their ability to respond to IL-2 and to absorb IL-2 were not observed. Absolute numbers of OKT 8 positive cells in PBMC of patients with good prognosis were significantly decreased after surgery and chemotherapy, while those of OKT 4 positive cells remained unchanged. Although IL-2 production in PBMC of patients with good prognosis was significantly elevated after chemotherapy, that in PBMC of patients with poor prognosis declined to about a half of pre-operative levels. The ability of PBMC to respond to IL-2 was significantly elevated not only in patients with good prognosis but also in patients with poor prognosis after termination of chemotherapy. On the other hand, the ability of PBMC to absorb IL-2 remained unchanged during the course of treatment. These findings may contribute to the understanding of tumor-induced immune suppression.

Citing Articles

A biobehavioral model of cancer stress and disease course.

Andersen B, Kiecolt-Glaser J, Glaser R Am Psychol. 1994; 49(5):389-404.

PMID: 8024167 PMC: 2719972. DOI: 10.1037//0003-066x.49.5.389.

References

Reinherz E, Kung P, Goldstein G, Schlossman S . Separation of functional subsets of human T cells by a monoclonal antibody. Proc Natl Acad Sci U S A. 1979; 76(8):4061-5. PMC: 383977. DOI: 10.1073/pnas.76.8.4061. View

Gillis S, Ferm M, Ou W, Smith K . T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978; 120(6):2027-32. View

Okada M, Henney C . The differentiation of cytotoxic T cells in vitro. III. The role of helper T cells and their products in the differentiation of cytotoxic cells from "memory" cell populations. J Immunol. 1980; 125(2):850-7. View

Reinherz E, Kung P, Goldstein G, Schlossman S . Further characterization of the human inducer T cell subset defined by monoclonal antibody. J Immunol. 1979; 123(6):2894-6. View

Elgert K, Farrar W . Suppressor cell activity in tumor-bearing mice. I. Dualistic inhibition by suppressor T lymphocytes and macrophages. J Immunol. 1978; 120(4):1345-53. View

Dennert G . Cloned lines of natural killer cells. Nature. 1980; 287(5777):47-9. DOI: 10.1038/287047a0. View

Strausser J, Rosenberg S . In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens. J Immunol. 1978; 121(4):1491-5. View

Farrar J, Simon P, Koopman W . Biochemical relationship of thymocyte mitogenic factor and factors enhancing humoral and cell-mediated immune responses. J Immunol. 1978; 121(4):1353-60. View

Paranjpe M, Boone C . Kinetics of the anti-tumor delayed hypersensitivity response in mice with progressively growing tumors: stimulation followed by specific suppression. Int J Cancer. 1974; 13(2):179-86. DOI: 10.1002/ijc.2910130205. View

10.

Hancock E, Kilburn D, LEVY J . Helper cells active in the generation of cytotoxicity to a syngeneic tumor. J Immunol. 1981; 127(4):1394-7. View

11.

Thurman G, Maluish A, Rossio J, Schlick E, Onozaki K, Talmadge J . Comparative evaluation of multiple lymphoid and recombinant human interleukin-2 preparations. J Biol Response Mod. 1986; 5(1):85-107. View

12.

Pross H, Baines M . Spontaneous human lymphocyte-mediated cytotoxicity againts tumour target cells. I. The effect of malignant disease. Int J Cancer. 1976; 18(5):593-604. DOI: 10.1002/ijc.2910180508. View

13.

Lotze M, Matory Y, Ettinghausen S, Rayner A, Sharrow S, Seipp C . In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol. 1985; 135(4):2865-75. View

14.

Kern D, Gillis S, Okada M, Henney C . The role of interleukin-2 (IL-2) in the differentiatin of cytotoxic T cells: the effect of monoclonal anti-IL-2 antibody and absorption with IL-2 dependent T cell lines. J Immunol. 1981; 127(4):1323-8. View

15.

Reinherz E, Kung P, Breard J, Goldstein G, Schlossman S . T cell requirements for generation of helper factor(s) in man: analysis of the subsets involved. J Immunol. 1980; 124(4):1883-7. View

16.

Farrar W, Elgert K . Inhibition of mitogen and immune blastogenesis by two distinct populations of supressor cells present in the spleens of fibrosarcoma-bearing mice: adoptive transfer of suppression. Int J Cancer. 1978; 22(2):142-51. DOI: 10.1002/ijc.2910220207. View

17.

Jurin M, Suit H . In vitro activity of lymphocytes and serum of C3Hf-Bu mice during the growth of methylcholanthrene-induced tumor and its regression following local irradiation. Cancer Res. 1974; 34(4):672-8. View

18.

Baker P, Gillis S, Ferm M, Smith K . The effect of T cell growth factor on the generation of cytolytic T cells. J Immunol. 1978; 121(6):2168-73. View

19.

Thomas Y, Sosman J, Irigoyen O, Friedman S, Kung P, Goldstein G . Functional analysis of human T cell subsets defined by monoclonal antibodies. I. Collaborative T-T interactions in the immunoregulation of B cell differentiation. J Immunol. 1980; 125(6):2402-8. View

20.

SIDKY Y, Auerbach R . Lymphocyte-induced angiogenesis in tumor-bearing mice. Science. 1976; 192(4245):1237-8. DOI: 10.1126/science.5775. View